<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828828</url>
  </required_header>
  <id_info>
    <org_study_id>SBMU 87-01-120-6003</org_study_id>
    <nct_id>NCT00828828</nct_id>
  </id_info>
  <brief_title>Antibody Response to Influenza Vaccine in Patients With Sarcoidosis</brief_title>
  <acronym>IVS</acronym>
  <official_title>Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of influenza vaccine (antibody
      response) in patients with sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcoidosis is a multisystem disease with unclear etiology characterized by the presence of
      noncaseating granuloma[1]. T helper cells response is exaggerated at the site of disease and
      cellular immunity depressed in peripheral blood[2]. Cutaneous anergy, lymphopenia and
      inversion of CD4/CD8 ratio in peripheral blood suggest T helper cells involvement[3].

      The action of humeral immune system in sarcoidosis is a matter of controversy. Standard
      hepatitis B virus vaccination did not provoke protective antibody titer in patients with
      sarcoidosis[3]. Although antibody response against influenza vaccine in patients with
      sarcoidosis is not well described, this vaccine is highly recommended in patients with
      chronic pulmonary diseases such as asthma, COPD and fibrosis [4, 5, 6]. In this study we aim
      to evaluate the humeral response to the influenza vaccine in sarcoidosis patients and assess
      vaccine safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serologic Response (equal or more than 4 fold HI titer rise) to each of the 3 antigens of the trivalent vaccine of the 2008-9 influenza vaccine</measure>
    <time_frame>4-6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of change in the antibody titer against each of the 3 antigenes of the trivalent vaccine of the 2008/2009 season [A/Brisbane/59/2007(HIN1)-like virus;A/Brisbane/10/2007(H3N2)-like virus;B/Florida/4/2006-like virus]</measure>
    <time_frame>4-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protective Antibody (equal or more than 1:40) titer after vaccination</measure>
    <time_frame>4-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Safety (any major or minor side effects)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <description>Sarcoidosis patients who are assigned to receive influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy controls who are assigned to receive influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>One 0.5 ml dose of influenza vaccine injected intramuscular.</description>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>2008-2009 vaccination campaign of influenza (Solvay Pharma)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Caes are defined as patients known as sarcoidosis and are under follow up at a tertiary
        care hospital clinic. Age and sex matched healthy healthcare workers serve as controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Sarcoidosis patients:

          -  Patients with relevant clinical, radiologic and histologic features of sarcoidosis
             (all stages).

          -  Signed informed consent.

        Exclusion Criteria:

          -  Organ failure (kidney, heart, liver).

          -  Collagen vascular diseases.

          -  Diabetes.

          -  Contraindications of vaccine (Egg allergy).

          -  Patients who receive high dose (&gt; 60 mg/day) steroid therapy.

          -  Any acute disease.

          -  Conditions accompanied by immunosuppression (like organ transplantation, HIV).

          -  Any psychological disease that interferes with regular follow-up.

          -  Inoculation with influenza vaccine within the past 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryam Keshtkar-Jahromi, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Research &amp; Development Center, Shahid Modarres Hospital, Shahid Beheshti University (MC), Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sasan Tavana, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Research &amp; Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marzieh Keshtkar-Jahromi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research &amp; Developement Center, Shahid Modares Hospital, Shahid Beheshti University (MC), Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amirsoheil Talebian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research &amp; Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Rahnavardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research &amp; Developement Center, Shahid Modares Hospital,Shahid Beheshti University (MC), Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talat Mokhtari-Azad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Modarres Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>1998734383</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997 Apr 24;336(17):1224-34. Review. Erratum in: N Engl J Med 1997 Jul 10;337(2):139.</citation>
    <PMID>9110911</PMID>
  </reference>
  <reference>
    <citation>MÃ¼ller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J. 1998 Sep;12(3):716-38. Review.</citation>
    <PMID>9762805</PMID>
  </reference>
  <reference>
    <citation>Mert A, Bilir M, Ozaras R, Tabak F, Karayel T, Senturk H. Results of hepatitis B vaccination in sarcoidosis. Respiration. 2000;67(5):543-5.</citation>
    <PMID>11070460</PMID>
  </reference>
  <reference>
    <citation>Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. J Asthma. 2007 Dec;44(10):817-22.</citation>
    <PMID>18097856</PMID>
  </reference>
  <reference>
    <citation>Ayabe E, Kaneko N, Ohkuni Y, Misawa M, Inoue K, Tanabe Y, Yasui D, Sato C, Mitsuishi Y, Nakashita T, Motojima S. [The efficacy of influenza vaccine for acute exacerbation of chronic obstructive lung disease in elderly patients]. Nihon Kokyuki Gakkai Zasshi. 2008 Jul;46(7):511-5. Japanese.</citation>
    <PMID>18700566</PMID>
  </reference>
  <reference>
    <citation>Wat D, Gelder C, Hibbitts S, Bowler I, Pierrepoint M, Evans R, Doull I. Is there a role for influenza vaccination in cystic fibrosis? J Cyst Fibros. 2008 Jan;7(1):85-8. Epub 2007 Jul 5.</citation>
    <PMID>17616444</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>May 20, 2009</last_update_submitted>
  <last_update_submitted_qc>May 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maryam Keshtkar-Jahromi</name_title>
    <organization>Clinical Research &amp; DevelopmentCenter, Shaheed Modarres Hospital, Shaheed Beheshti Medical University, Tehran, Iran.</organization>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

